胃泌素释放肽前体及神经元特异性烯醇化酶对小细胞肺癌的诊断价值

详细信息    查看全文 | 推荐本文 |

英文篇名：Research on the diagnostic value of pro-gastrin releasing peptide and neuron specific enolase in small cell lung cancer 作者：单娟 ; 丁涤非 ; 刘林龙 ; 李珊珊 英文作者：SHAN Juan;DING Difei;LIU Linlong;LI Shanshan;Department of Oncology, PLA 902 Hospital;Department of Infectious Disease, PLA 902 Hospital; 关键词：胃泌素释放肽前体 ; 神经元特异性烯醇化酶 ; 小细胞肺癌 ; 肿瘤标志物 ; 联合检测 英文关键词：pro-gastrin releasing peptide;;neuron specific enolase;;small cell lung cancer;;tumor marker;;combined detection 中文刊名：AZJZ 英文刊名：Oncology Progress 机构：解放军联勤保障部队第九〇二医院肿瘤科;解放军联勤保障部队第九〇二医院传染科; 出版日期：2019-07-25 出版单位：癌症进展 年：2019 期：v.17 语种：中文; 页：AZJZ201914021 页数：3 CN：14 ISSN：11-4971/R 分类号：88-90

摘要

目的探讨胃泌素释放肽前体(ProGRP)和血清神经元特异性烯醇化酶(NSE)在小细胞肺癌(SCLC)诊断中的临床应用价值。方法分别采用化学发光微粒子免疫检测法和免疫发光夹心法检测31例SCLC患者和36例非小细胞肺癌(NSCLC)患者血清中的ProGRP和NSE水平,并分析二者对SCLC的诊断价值。结果SCLC组患者ProGRP、NSE水平均高于NSCLC组患者,差异均有统计学意义(P﹤0.05),且ProGRP诊断SCLC的灵敏度和特异度均高于NSE。结论与NSE比较,血清ProGRP作为诊断SCLC的肿瘤标志物,具有灵敏度、特异度高的特点,在SCLC的诊断中有重要的临床应用价值。
        Objective To explore the clinical diagnostic value of pro-gastrin releasing peptide(ProGRP) and serum neuron specific enolase(NSE) in the detection of small cell lung cancer(SCLC). Method ProGRP and NSE levels in the serum of 31 patients with SCLC and 36 patients with non-small cell lung cancer(NSCLC) were measured by chemiluminescent microparticle immunoassay and immunoluminescence sandwich immunoassay, respectively, and their diagnostic value for SCLC were analyzed. Result The levels of ProGRP and NSE in SCLC group were significantly higher than those in NSCLC group, showing statistically significant differences(P<0.05). The sensitivity and specificity of ProGRP in diagnosing SCLC were both higher compared to NSE. Conclusion Serum ProGRP is more sensitive and specific than NSE as a tumor marker in the diagnosis of SCLC, and it is of important clinical value in the diagnosis of SCLC.

引文

[1]陈名声,徐焰,刘田,等.胃泌素释放肽前体和神经元特异性烯醇化酶联合检测在小细胞肺癌诊断中的应用[J].内蒙古中医药, 2010, 29(2):1-2.
    [2]潘建芳,徐水土,郑岩,等.肺癌患者化疗前后生活质量情况及影响因素分析[J].中华全科医学, 2016, 14(5):754-756; 792.
    [3]张爽,柳菁菁,程颖.小细胞肺癌个体化治疗进展[J].中国肿瘤临床, 2017, 44(12):571-576.
    [4] Carter L, Rothwell DG, Mesquita B, et al. Molecular analysis of circulating tumor cells identifies distinct copy-number profiles in patients with chemosensitive and chemorefractory small-cell lung cancer[J]. Nat Med, 2017, 23(1):114-119.
    [5]齐鲁,丁彦青.肺癌基因异常表达与化疗药物的相关性分析[J].肿瘤防治研究, 2014, 41(5):405-408.
    [6] McDondld TJ, Nilsson G, Vagne M, et al. A gastrin releasing peptide from the porcine nonantral gastric tissue[J].Gut, 1978, 19(9):767-774.
    [7]李佳,齐军.小细胞肺癌相关肿瘤标志物的研究进展[J].标记免疫分析及临床, 2015, 12(22):1293-1296.
    [8] Ischia J, Patel O, Shulkes A, et al. Gastrin-releasing peptide:different forms, different functions[J]. Biofactors,2009, 35(1):69-75.
    [9] Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency[J]. Am J Kidney Dis, 2002, 39(5):930-936.
    [10]杨静静,黄猛,杨佳锦,等.胃泌素释放肽前体的研究进展[J].国际检验医学杂志, 2013, 34(3):337-338.
    [11]李德经,宁国兰,柳兆飞,等. ProGRP和NSE对小细胞肺癌的诊断及疗效评估的价值[J].实用医学杂志, 2016, 32(5):754-758.
    [12]夏春伟,陈文萍,徐玲,等.血清CEA、CYFRA21-1与非小细胞肺癌化疗疗效及预后的临床研究[J].临床肺科杂志, 2011, 16(12):1900-1901.
    [13]张国云,周春宇,刘晓岚.非小细胞肺癌放疗前后血清肿瘤标记物的改变及其临床意义[J].中国实验诊断学,2011, 15(5):851-852.
    [14]王冠军,赫杰.肿瘤学概论[M].北京:人民卫生出版社,2013:76.
    [15] Wang X, Liu M, Zhang L, et al. Syndrome of inappropriate antidiuretic hormone secretion:a poor prognosis in small-cell lung cancer[J]. Arch Med Res, 2016, 47(1):19-24.